2013, Number 1
<< Back Next >>
Acta Pediatr Mex 2013; 34 (1)
Retreatment with intravenous immunoglobulin (IVIG) of refractory Guillain-Barre syndrome in children
Rodríguez-Lozano AL, Rivas-Larrauri F, Dávila-Gutiérrez G, Herrera-Aguirre G, Hernández-Bautista VM
Language: Spanish
References: 11
Page: 48-50
PDF size: 163.35 Kb.
ABSTRACT
Guillain-Barré syndrome (GBS) is an acute symmetrical paralyzing
disease due to a demyelinating polyrradiculoneuropathy,
often induced by a preceding infection. The main modalities
for the treatment of GBS include plasmapheresis and intravenous
immune globulin. Reports of the use of IVIG in children
with GBS are limited: 1 g/kg for two days or 400 mg/kg for five
days. While these studies in children are not definitive because
of design limitations, their results are consistent with the larger
randomized trials in adults.
REFERENCES
Jones HR Jr. Guillain-Barré Syndrome: perspectives with infants and children. Semin Pediatr Neurol 2000;7:91.
Hughes RAC, Swan AV, van Doorn PA, Intravenous immunoglobulin for Guillain-Barré syndrome (Review), The Cochrane Library 2010 Issue 6.
DiMario FJ. Intravenous Immunoglobulin in the treatment of Childhood Guillain-Barré Syndrome: A Randomized Trial. Pediatrics 2005;116: 226-8.
Sundel R, Burns J, Baker A, Beiser A, Newburger JW. Gammaglobulin retreatment in Kawasaki disease. J Pediatr 1993;123:657-9.
Van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008;7:939-50.
Hughes RAC, Wijdicks EFM, Barohn R, Benson E, Conrblath OR, Hahn AF, Meythaler JM, Miller RG, Sladky JT, Stevens JC. Practice parameter: Immunotherapy for Guillain-Barré syndrome: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003;61:763-40.
Peake D, Withehouse WP, Philip S. The management of Guillain-Barré syndrome. Current Paediatrics 2004;14:252-7.
Van der Meché FGA, van Doorn PA. Guillain-Barré syndrome. Curr Treat Options Neurol 2000;2(6):507-16.
Korinthenberg R, Schessl J, Kirschner J, Mönting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré Syndrome: a randomized trial. Pediatrics 2005;116:8-14.
Durongpisitkul K, Soongswang J, Laohaprasitiporn A, et al. Immunoglobulin failure and retreatment in Kawasaki Disease. Pediatr Cardiol 2003;24 (2):145-8.
Farcas P, Avnun L, Frisher S, Herishanu YO, Wirguin I. Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome. Lancet 1997;350:1747.
Full text